Shots:
- The approval is based on P-III CASPIAN trial assessing Imfinzi + SoC (etoposide & carboplatin/ cisplatin CT) or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200 centers across 23 countries
- Results: the study met its 1EPs of OS in Jun’19, demonstrating a 27% reduction in risk of death with m-OS (13.0 vs 10.3mos.); ORR (68% vs 58%). An updated analysis demonstrated sustained efficacy after a median follow up 2+ yrs. with m-OS (12.9 vs 10.5mos.), alive patients (22.2% vs 14.4%) @24mos., safety & efficacy results were consistent with results in the overall global trial population
- Imfinzi is a mAb targeting PD-L1 & blocks interaction of PD-L1 with PD-1 & CD80
Click here to read the full press release/ article | Ref: AstraZeneca | Image: Mint
The post AstraZeneca’s Imfinzi (durvalumab) Receives NMPA’s Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer first appeared on PharmaShots.
